Allergy Therapeutics PLC Company to Host Key Allergy Conference
July 02 2015 - 2:00AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
02 July 2015
2 July 2015
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Company to Host Key Allergy Conference
Allergy Therapeutics, the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, today
announces that it is hosting the Eighth Annual Adjuvants in Allergy
Conference in Amsterdam on the 2-4 July.
At the conference, Dr. Albert Roger Director of the Allergy Unit
at Universitari Hospital Germans Trias Pujol, Badalona Spain, will
present data from the Company's recent Acarovac efficacy study for
the treatment against house dust mite allergy. Acarovac has been
Allergy Therapeutics strongest growing treatment in Spain this year
and it is one of the Company's new generation of products developed
to address the perennial allergy market with innovative and
short-course therapies.
The conference provides an outstanding opportunity for
scientific debate and dialogue amongst 200 specialists in
respiratory diseases and allergology from all over Europe and
America. New perspectives and innovations in allergy treatment will
be presented by international key opinion leaders in order to
initiate the process of global shared knowledge in these areas and
ultimately lead to improvements in patient outcomes.
There is an exciting programme of topics to facilitate in-depth
discussions, which include, the impact for allergists on changes to
the climate and migration patterns, the distribution of pollen
counts and their annual patterns, the generation and maintenance of
allergen specific T-cell tolerance, options and strategies for
primary and secondary prevention of atopy and asthma, and the
dramatic increase in the prevalence of allergic diseases.
Manuel Llobet, Chief Executive Officer, commented:
"Allergy Therapeutics is proud to host the Eighth Annual
Adjuvants in Allergy Conference, a highly scientific open forum to
discuss allergy topics with expert key opinion leaders and
allergists from around the world. The aim of the conference is to
encourage the medical community to consider innovative solutions
for patients suffering from allergies and we are excited to be at
the forefront of these discussions."
For more information on the conference and a programme outline,
please use the following link:
http://www.allergytherapeutics.nl/files/2914/2167/1597/ATL_program.pdf.
-Ends-
For further information:
Allergy Therapeutics +44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
Panmure Gordon +44 (0) 20 7886 2500
Freddy Crossley / Peter Steel / Duncan Monteith,
Corporate Finance
Tom Salvesen, Corporate Broking
FTI Consulting +44 (0) 20 3727 1000
Simon Conway
Victoria Foster Mitchell
Note to editors
About Adjuvants in Allergy
Adjuvants in Allergy provides an outstanding opportunity for
scientific debate and dialogue among 200 specialists in respiratory
diseases and allergology from all over Europe and America. The
purpose of this educational meeting is to highlight different
diagnostic and therapeutic aspects as presented by expert key
opinion leaders who will review the current state of knowledge in
these areas.
New perspectives and innovations in allergy treatment will
include:
-- Significant changes to the climate and migration patterns
present new therapeutic and diagnostic demands for the allergist.
These changes, although global, particularly impact clinical care
in Europe.
-- The distribution of pollen counts and their annual patterns.
This, together with services that provide personalised predictions
for patients will be discussed. The future of allergic disease
therapy will be explored through the latest scientific data
including how environmental factors precipitate disease in people
with inherited susceptibilities and how to enhance diagnostic
accuracy via the recognition of environmental risk factors.
-- Another important step forward in the allergy field is the
generation and maintenance of allergen specific T-cell tolerance.
The latest data on therapy induced changes to the innate immune
system will be discussed together with a discussion of the efficacy
and duration of therapy.
-- The opportunity to achieve sustained disease modification
will be explored and the importance of this research in clinical
practice will be emphasised. The significant consequences of
allergic disease on quality of life have driven research to
understand how allergy vaccines might prevent the onset of allergic
disease. This will be discussed in the context of the options and
strategies for primary and secondary prevention of atopy and
asthma.
-- Additionally, the latest thinking on adjuvants that enhance
the immune response will be explored. A major development in
disease modifying agents which aim to restore the Th1 balance
rather than Th2 has potential in therapy for allergic disease.
Erika Jensen-Jarolim will provide a critical overview about
aluminium used as an adjuvant in vaccination and immunotherapy.
Thomas Kuendig will characterise the "ideal adjuvant", whereas two
further presentations will focus on MPL - an adjuvant successfully
introduce into immunotherapy by Allergy Therapeutics in 1999.
-- Finally, one important aspect concerns the dramatic increase
in the prevalence of allergic diseases. The hygiene hypothesis has
now changed to the microbial exposure hypothesis, where exposure to
microbes is closely linked to the development of the early immune
system and allergic disease. The intestinal flora may contribute to
allergic disease through its substantial effect on mucosal
immunity. Based on findings that exposure to microbial flora early
in life can change the Th1/Th2 balance towards a Th1 cell response,
we will discuss how probiotics may be beneficial in preventing
allergic disease.
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company
focused on allergy vaccination. It has a growing business achieving
revenue in the last financial year of GBP42 million mainly in
Europe through its own sales and marketing infrastructure and
further afield through distributors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUMWMUPAPPG
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
